Clinical Trials Directory

Trials / Unknown

UnknownNCT00006056

Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
40 (planned)
Sponsor
Fairview University Medical Center · Academic / Other
Sex
All
Age
0 Years – 55 Years
Healthy volunteers
Not accepted

Summary

OBJECTIVES: I. Determine the efficacy of unrelated donor hematopoietic stem cell transplantation in the treatment of patients with life threatening hemophagocytic disorders. II. Determine the rate of disease free survival, incidence of graft failure, and incidence of graft versus host disease in these patients after undergoing this treatment regimen.

Detailed description

PROTOCOL OUTLINE: Patients receive oral busulfan twice a day on days -9 to -6; cyclophosphamide IV over 1 hour on days -5 to -2; etoposide IV over 4 hours on days -5 to -3; and anti-thymocyte globulin IV twice a day on days -2 and -1 and days 1 and 2. Patients undergo allogeneic hematopoietic stem cell transplantation on day 0. Filgrastim (G-CSF) is administered subcutaneously beginning on day 1 and continuing until blood counts recover. Patients receive graft versus host disease prophylaxis with methotrexate IV on days 1, 3, 6, and 11 and cyclosporine IV over 1-4 hours (orally once the patients resumes eating) every 12 hours (every 8 hours for pediatric patients) starting on or prior to day -3 and continuing up to 1 year. Patients are followed at days 28 and 100, at 6 months and 1 year, and then annually for 5 years.

Conditions

Interventions

TypeNameDescription
DRUGanti-thymocyte globulin
DRUGbusulfan
DRUGcyclophosphamide
DRUGcyclosporine
DRUGetoposide
DRUGfilgrastim
DRUGmethotrexate
PROCEDUREallogeneic hematopoietic stem cell transplantation

Timeline

Start date
2000-03-01
First posted
2000-07-06
Last updated
2005-06-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00006056. Inclusion in this directory is not an endorsement.